Skip to main content
ACHV logo

ACHV

Achieve Life Sciences, Inc.

Trade Ideas Performance

Latest Closed Trade Idea

Loading...
We are loading your data. Please wait a moment.

Sentiment

News

0

Social

0

About

Events of Achieve Life Sciences, Inc. (ACHV)

In the past six months, ACHV's stock rose approximately 31% over 30 days and 70% over three months leading up to late August 2026. The company received a Complete Response Letter (CRL) from the FDA in June 2026 for its cytisinicline NDA, addressing manufacturing and labeling items without citing efficacy or safety deficiencies. ACHV targets an NDA resubmission in Q4 2026, with potential U.S. approval and commercial launch in H1 2027. The company also strengthened its balance sheet with a private placement of up to $354 million, including $180 million upfront, joined the Russell 2000® Index in June 2026, and appointed Benjamin Halladay as CFO in October 2026.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)